Copanlisib - Bayer HealthCare Pharmaceuticals

Drug Profile

Copanlisib - Bayer HealthCare Pharmaceuticals

Alternative Names: Aliqopa; BAY-806946; BAY-841236; Copanlisib hydrochloride

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer All Ireland Cooperative Oncology Research Group; Bayer HealthCare Pharmaceuticals; Chonnam National University Hospital; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA)
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Morpholines; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Follicular lymphoma
  • Phase III Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Phase II Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Mantle-cell lymphoma
  • Phase I/II Breast cancer; Peripheral T-cell lymphoma; Solid tumours

Most Recent Events

  • 14 Jun 2018 Efficacy and adverse events data from the phase II CHRONOS-1 trial in Non-Hodgkin's lymphoma presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 01 Jun 2018 Drug interactions data from a phase I trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 08 May 2018 Bayer plans the ROCOCO phase I trial for Solid tumours in Germany , (NCT03517956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top